Avidity Biosciences (Nasdaq: RNA) announced it will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will cover new data from their EXPLORE44 program for Duchenne muscular dystrophy (DMD44) and insights into myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). Additionally, Avidity will host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Avidity Biosciences (Nasdaq: RNA) announced it will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will cover new data from their EXPLORE44 program for Duchenne muscular dystrophy (DMD44) and insights into myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). Additionally, Avidity will host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.